London: Sage Therapeutics said on Tuesday that its Experimental drug found to be safe and showed some effectiveness in rare patients, genetic neurological conditions called Huntington’s disease in a part of Mid-stage study,
However, the company said the study, conducted on patients with Huntington’s disease, was not designed to show a statistically significant difference between the delazenmador drug and placebo.
The company’s shares initially surged as much as 80 per cent but later erased those gains and fell 1.6 per cent in volatile pre-market trading.
The news comes after the failure of a mid-stage trial of the same drug in April, when it was tested on patients with Parkinson’s disease.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)
sage-therapeutics-says-rare-disease-drug-found-to-be-safe-in-mid-stage-study-et-healthworld-pharma
